Faropenem

Jump to: navigation, search
Faropenem
Faropenem Wiki Str.png
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H15NO5S
Molar mass285.317 g/mol

WikiDoc Resources for Faropenem

Articles

Most recent articles on Faropenem

Most cited articles on Faropenem

Review articles on Faropenem

Articles on Faropenem in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Faropenem

Images of Faropenem

Photos of Faropenem

Podcasts & MP3s on Faropenem

Videos on Faropenem

Evidence Based Medicine

Cochrane Collaboration on Faropenem

Bandolier on Faropenem

TRIP on Faropenem

Clinical Trials

Ongoing Trials on Faropenem at Clinical Trials.gov

Trial results on Faropenem

Clinical Trials on Faropenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Faropenem

NICE Guidance on Faropenem

NHS PRODIGY Guidance

FDA on Faropenem

CDC on Faropenem

Books

Books on Faropenem

News

Faropenem in the news

Be alerted to news on Faropenem

News trends on Faropenem

Commentary

Blogs on Faropenem

Definitions

Definitions of Faropenem

Patient Resources / Community

Patient resources on Faropenem

Discussion groups on Faropenem

Patient Handouts on Faropenem

Directions to Hospitals Treating Faropenem

Risk calculators and risk factors for Faropenem

Healthcare Provider Resources

Symptoms of Faropenem

Causes & Risk Factors for Faropenem

Diagnostic studies for Faropenem

Treatment of Faropenem

Continuing Medical Education (CME)

CME Programs on Faropenem

International

Faropenem en Espanol

Faropenem en Francais

Business

Faropenem in the Marketplace

Patents on Faropenem

Experimental / Informatics

List of terms related to Faropenem

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Faropenem is an orally-active beta-lactam antibiotic belonging to the penem group. It is the first orally-active penem antibiotic. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.

  • The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (PubChem 636379)
  • The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem but company officials recently announced that this name was rejected by the FDA. (Q1 06 Investor Conf Call)(PubChem 6918218)

The company also stated their hope to have the product available for commercial sale months before the 2007 influenza season.

Clinical use

Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application (NDA) dossier submitted included four proposed indications:

  • acute bacterial sinusitis
  • community acquired pneumonia
  • acute exacerbations of chronic bronchitis
  • uncomplicated skin and skin structure infections

External links



Linked-in.jpg